Prosecution Insights
Last updated: November 15, 2026
Application No. 18/562,953

An Isothermal Diagnostic Test that Utilizes a Cas Protein and a Polymerase

Final Rejection §102§103
Filed
Nov 21, 2023
Priority
Jun 10, 2021 — provisional 63/209,008 +2 more
Examiner
SALMON, KATHERINE D
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
New England Biolabs Inc.
OA Round
2 (Final)
43%
Grant Probability
Moderate
3-4
OA Rounds
81%
With Interview

Examiner Intelligence

Grants 43% of resolved cases
43%
Career Allowance Rate
342 granted / 801 resolved
-17.3% vs TC avg
Strong +38% interview lift
Without
With
+38.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
69 currently pending
Career history
921
Total Applications
across all art units

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This action is in response to papers filed 6/22/2026. Claims 1-3, 5-11, 13-14, 16-19 are pending. Claims 4,12,15 have been cancelled. The following rejections are newly applied by amendment. This action is FINAL. Withdrawn Objections and Rejections The objections made in the previous office action is withdrawn based upon amendments to the claims. The 35 USC 112b rejection made in the previous office action is withdrawn based upon amendments to the claims. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 and 3 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Robb et al. (US Patent Application Publication 2017/0283797 October 5, 2017). With regard to claims 1 and 3, Robb et al. teaches a container comprises a klenow and a mesophilic Cas protein (para 152 and 156). The limitation that the kit contains instructions; the inclusion of instructions is not considered to provide a patentable limitation on the claims because the instructions merely represent a statement of intended use in the form of instructions in a kit. See In re Ngai, 367 F.3d 1336, 70 U.S.P.Q.2d 1862 (Fed. Cir. 2004) (holding that an inventor could not patent known kits by simply attaching new set of instructions to that product). The limitation of “with instructions for …” is considered printed instructions and does not limit the required structures. The term “kit” does not provide any structural limitations other than the structures recited. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-3, 5-11, 13-14, 16-19 is/are rejected under 35 U.S.C. 103 as being unpatentable over Doudna et al. (US Patent No. 10253365 April 9, 2019) in view of Bashikirov et al. (US Patent Application Publication 2019/0360039 November 28, 2019) and Robinson et al. (US Patent Application Publication 2018/0100181 April 12, 2018) With regard to claims 1-2, 5, Doudna et al. teaches a BSU DNA polymerase and CAS12a (e.g. mesophilic) (para 115-118). Although Dounda et al does not teach that these chemicals are within the same container, it would be obvious that polymerases and Cas proteins can be mixed together in a single tube for analysis. The limitation that the kit contains instructions, the inclusion of instructions is not considered to provide a patentable limitation on the claims because the instructions merely represent a statement of intended use in the form of instructions in a kit. See In re Ngai, 367 F.3d 1336, 70 U.S.P.Q.2d 1862 (Fed. Cir. 2004) (holding that an inventor could not patent known kits by simply attaching new set of instructions to that product). The limitation of “with instructions for …” is considered printed instructions and does not limit the required structures. The term “kit” does not provide any structural limitations other than the structures recited. However, Doudna et al. does not specifically teach that a klenow fragment. With regard to claims 6, Doudna et al. teaches the structure of Cas12a (para 105-106). Although Doudna et al. does not teach SEQ ID NO. 10, the structure of the CAS12A protein of Doudna et al. would encompass the sequence. With regard to claim 7, Doudna et al. teaches a reverse transcriptase (para 116). With regard to claim 8, Doudna et al. teaches LAMP using primers (para 116). With regard to claim 9, Doudna et al. teaches that that reagents can be placed on a substrate (e.g. immobilized on a matrix) (para 263). With regard to claim 10, 17, Doudna et al. teaches a method of combining RNA, BSU, CAS12a, LAMP and reverse transcriptase (para 115-119). However, Doudna et al. does not teach the LAMP temperatures. With regard to claim 13, Doudna et al. teaches a method of using quencher and fluorophore (para 5). With regard to claim 14, As Doudna et al. teaches the LAMP assay, Doudna et al. teaches the steps of claim 14. With regard to claim 16, Doudna et al. teaches 10- or more copies (para 95). Bashikirov et al. teaches a method of detecting target DNA comprising combining a sample with a reaction mixture with BSU LF and performing LAMP at 20 to 37 C(which is encompassed by the range) and detecting (para 149). With regard to claims 10-11 and 15-18, Bashikirov et al. teaches use of controls and reaction temperatures of less than 60C (para 149-152). Bashikirov et al. teaches a method of detecting target DNA comprising combining a sample with a reaction mixture with BSU LF and performing LAMP at 20 to 37 C(which is encompassed by the range) and detecting (para 149). . Bashikirov et al. teaches a method of detecting target DNA comprising combining a sample with a reaction mixture with BSU LF and performing LAMP at 20 to 37 (which is encompassed by the range) and detecting (para 149). With regard to claims 1, 3, 10, 15 and 18, Robinson et al. teaches that LAMP assays can be performed using BSsu or Klenow fragments (para 101). Further, Robinson teaches that the sample concentration can be 100 pg (para 6). Therefore it would be prima facie obvious to one of ordinary skill in the art at the time of filing to modify the method and composition of Doudna et al. to further include the LAMP reaction steps of Bashikirov et al and the fragments of Klenow of Robinson et al. The ordinary artisan would be motivated to use the temperature reaction steps of Bashikirov et al in order to perform the LAMP method of Doudna et al. Furhtermore it would be obvious to one of ordinary skill that BSU can be interchanged with Klenow fragments in the LAMP assay based upon the teachings of Robinson. Response to Arguments The reply traverses the rejection. The reply asserts that the references do not encompass the temperature steps in a one step reaction (p. 10). These arguetmsn have been reviewed but are not found persuasive. It is noted that the claims are not limited to one step methods. Furhtermore, the temperatures of Bashikirov et al are encompassed in the range of the claims. As such the rejections are maintained. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE D SALMON whose telephone number is (571)272-3316. The examiner can normally be reached 9-530. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu Cheng (Winston) Shen can be reached at 5712723157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATHERINE D SALMON/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Nov 21, 2023
Application Filed
Feb 20, 2026
Non-Final Rejection mailed — §102, §103
Jun 22, 2026
Response Filed
Sep 15, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767985
METHODS OF DIAGNOSING A DISEASE STATE
5y 4m to grant Granted Oct 20, 2026
Patent 12760366
METHODS FOR DETERMINING RESPONSIVENESS TO ANTI-TUMOR NECROSIS FACTOR THERAPY IN THE TREATMENT OF PSORIASIS
4y 6m to grant Granted Oct 13, 2026
Patent 12748103
METHODS FOR SELECTING AND TREATING CANCER WITH FGFR3 INHIBITORS
3y 9m to grant Granted Sep 29, 2026
Patent 12729405
METHOD AND KIT FOR DETERMINING BENEFIT OF CHEMOTHERAPY
4y 6m to grant Granted Sep 08, 2026
Patent 12709776
NOVEL MARKER OF EPITHELIAL-MESENCHYMAL TRANSITION IN PANCREATIC CANCER
4y 12m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
43%
Grant Probability
81%
With Interview (+38.2%)
Moderate
PTA Risk
Based on 801 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month